Jason Aryeh

Jason Aryeh has bought as well as sold, but not in the same proportions: 19 purchases worth EUR 2,234,234 (median EUR 24,708) and 27 sales worth EUR 26,275,510 (median EUR 517,487). Purchases make up 41% of the open-market trades. The largest, EUR 1,542,018 on September 16, 2016, concerns Aralez Pharmaceuticals Inc.

The three largest sales are all at Ligand Pharmaceuticals Inc: EUR 5,712,143 on August 17, 2018, EUR 2,905,015 on November 17, 2017 and EUR 2,511,193 on February 27, 2017. Ligand Pharmaceuticals Inc holds 51 of the 76 filings, as Director, ahead of Orchestra BioMed Holdings, Inc. (7), Aralez Pharmaceuticals Inc. (6), Merrimack Pharmaceuticals Inc (4, 10% Owner) and QLT Inc/BC (4).

The largest yearly volume is 2019 (17 filings), followed by 2016 (14) and 2017 (13), with just one filing a year in 2020, 2021 and 2022. Over the last twelve months there are 5 filings, 2 of them sales. The median publication delay is 2 days.

For 13 purchases with a stored 90-day result, the median is minus 13.2% and 46% are positive (past results on record, not a forecast). Aryeh has 24, 16 and 12 own market trades within 30 days of colleagues at Ligand Pharmaceuticals Inc, in that order. In the same direction: 24, 10 and 12. In the same order, the colleagues are John L. Higgins, John W. Kozarich and Matthew W. Foehr.